重组大肠杆菌

NR-19571?? Streptococcus pneumoniae Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4(Clones)|Streptococcus pneumoniae|Streptococcus pneumoniae Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Streptococcus pneumoniae Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 4, NR-19571."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Streptococcus pneumoniae (S. pneumoniae) Gateway^? clone set consists of approximately 2029 sequence validated clones from S. pneumoniae strain TIGR4 cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with a native start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Clone plates are replicated using a BioMek^? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.

NR-19454?? Rickettsia prowazekii, Strain Madrid E, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 6(Clones)|Rickettsia prowazekii|Rickettsia prowazekii, Strain Madrid E, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 6|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Rickettsia prowazekii, Strain Madrid E, Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 6, NR-19454."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Rickettsia prowazekii (R. prowazekii), strain Madrid E, Gateway^? clone set consists of approximately 750 sequence validated clones from R. prowazekii, strain Madrid E, cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with an ATG start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Plate orientation and viability were confirmed for NR-19454.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Clone plates are replicated using a BioMek^? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.